Health

Alzheimer’s Drugs and AI in Healthcare

Updated 2026-05-11 08:45 UTC 1 source Neutral

Medicare spending on new Alzheimer’s drugs has been lower than expected due to complex administration. Opinions suggest a need for licensing frameworks and caution with AI integration.

Coverage timeline — 4 articles

STAT News

STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs

Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.

2026-05-11 08:30 UTC

STAT News

Opinion: AI doctors should be licensed. Here’s a framework to do that

A state-by-state approach to clinical AI won’t work. Here’s a framework that can.

2026-05-11 08:30 UTC

STAT News

Opinion: What addiction medicine can teach us about depending on AI

People gradually rely on AI to reduce the discomfort of thinking. For some, that can become a problem.

2026-05-11 08:30 UTC

STAT News

STAT+: Five years after disaster, a rare disease community gets new chance at treatment

Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.

2026-05-11 08:30 UTC